Develops drugs for hypercortisolism and related disorders.
Jun 2026Revenue $831M/yrExpenses $824M/yr
Expected to fall below break-even Jul 2026
Figures by year
Is Corcept Therapeutics still profitable?
Yes. In the 12 months to Jun 2026, revenue was $831M and expenses $824M. Its expenses are growing faster than its revenue, and the trends are projected to cross in Jul 2026.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $761M | $717M | $44.8M |
| Dec 2024 | $675M | $538M | $137M |
| Dec 2023 | $482M | $375M | $107M |
| Dec 2022 | $402M | $289M | $113M |
| Dec 2021 | $366M | $242M | $124M |
| Dec 2020 | $354M | $226M | $128M |
| Dec 2019 | $306M | $195M | $112M |
| Dec 2018 | $251M | $162M | $89.5M |
| Dec 2017 | $159M | $106M | $52.9M |
| Dec 2016 | $81.3M | $71.1M | $10.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.